Percival Barretto-Ko is the President & Chief Executive Officer of Plexium, Inc., a leading nextgeneration Targeted Protein Degradation (TPD) company. Percival joined Plexium in 2021 with extensive biopharmaceutical experience across various therapeutic areas, functions, and geographies. Through its comprehensive best-in-class TPD platform, powered by a proprietary ultra-high throughput cell-based screening (uHTS) technology, Plexium leads the way in the rational design and discovery of monovalent protein degraders across a wide range of modalities.

Prior to Plexium, Percival was the Chief Business Officer of Astellas Pharma Inc., where he spearheaded the execution of the company’s Corporate Strategic Plan and its efforts to enhance internal and external innovation. Percival’s earlier roles at Astellas included President of Astellas Pharma US, SVP Head of International, and SVP Head of Corporate Strategy, Business Development & Government Affairs. Before joining Astellas, Percival held increasingly senior commercial positions with the Roche Group in the United States and the United Kingdom.

Percival earned a BS in Biological Sciences and Chemistry with Honors from Cornell University and an MBA from Yale University. In addition, Percival served as a Sloan Fellow for Innovation and Global Leadership at the MIT Sloan School of Management, where he was awarded an MS degree in Management. Percival is a board member of Americares, a health-focused relief and development organization that serves people affected by poverty or disaster with life-changing medicine and health programs.